Holen Sie sich die Stockscreener-App
2.13
0.47%
0.010
Handel nachbörslich:
2.14
0.01
+0.47%
Schlusskurs vom Vortag:
$2.12
Offen:
$2.12
24-Stunden-Volumen:
72,408
Relative Volume:
1.11
Marktkapitalisierung:
$87.00M
Einnahmen:
$2.70M
Nettoeinkommen (Verlust:
$5.53M
KGV:
19.36
EPS:
0.11
Netto-Cashflow:
$-10.55M
1W Leistung:
+1.91%
1M Leistung:
+0.00%
6M Leistung:
-7.79%
1J Leistung:
-17.76%
1-Tages-Spanne:
$2.11
$2.18
1-Wochen-Bereich:
$2.09
$2.18
52-Wochen-Spanne:
$1.82
$3.09
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Firmenname
Oramed Pharmaceuticals Inc
Sektor
Branche
Telefon
646-844-1164
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Vergleichen Sie ORMP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.13 | 85.37M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-12 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-09 | Eingeleitet | National Securities | Buy |
| 2020-12-03 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-11 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-12-11 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Bestätigt | FBR Capital | Outperform |
| 2015-12-01 | Bestätigt | H.C. Wainwright | Buy |
| 2015-11-19 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-13 | Fortgesetzt | MLV & Co | Buy |
| 2014-01-30 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Eingeleitet | MLV & Co | Buy |
| 2013-12-03 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Oramed Pharmaceuticals Inc Aktie (ORMP) Neueste Nachrichten
What analysts say about Oramed Pharmaceuticals Inc. stockSkyrocketing profit margins - jammulinksnews.com
Is Oramed Pharmaceuticals Inc. a good long term investmentAccelerated capital growth - jammulinksnews.com
What drives Oramed Pharmaceuticals Inc. stock priceExceptional financial outcomes - jammulinksnews.com
Oramed Pharmaceuticals Inc. Stock Analysis and ForecastSuperior stock selection - jammulinksnews.com
Oral Proteins & Peptides Market to Surge to US$24 Billion by 2030, Driven by Chronic Disease Burden and Drug Delivery Innovation - Barchart.com
What makes Oramed Pharmaceuticals Inc. stock price move sharplyFree Group Entry - Newser
Why Oramed Pharmaceuticals Inc. stock attracts strong analyst attentionRisk Managed Trading Strategy - Newser
How Oramed Pharmaceuticals Inc. stock performs during market volatilityFree Investment Community - Newser
Head to Head Survey: Oramed Pharmaceuticals (NASDAQ:ORMP) and Smith & Nephew SNATS (NYSE:SNN) - Defense World
Alpha Tau Medical's $36.9M Financing: A Strategic Leap Toward Revolutionary Cancer Therapy - AInvest
Oramed Pharmaceuticals : Announces Xiaoming Gao Joins Board of Directors - marketscreener.com
Oral Biologics Market Outlook 2025: Rising Demand, Market Size, - openPR.com
Two Sigma Advisers LP Invests $662,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Type 2 Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com
Oral Biologics Market in 2025-2032 Detailed Study Analysis with - openPR.com
Alpha Tau to Present at Jefferies Global Healthcare Conference - Stock Titan
Acusphere (OTCMKTS:ACUS) versus Oramed Pharmaceuticals (NASDAQ:ORMP) Critical Comparison - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200-Day Moving Average – Should You Sell? - Defense World
Oramed Pharm Extends Stock Buyback Program - TipRanks
Dimensional Fund Advisors LP Grows Stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable - Yahoo Finance
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com - Defense World
Oramed: Q1 Earnings Snapshot - New Haven Register
Alpha Tau Medical appoints new board member By Investing.com - Investing.com India
Alpha Tau Medical appoints new board member - Investing.com
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors - GlobeNewswire
StockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to Sell - Defense World
Renaissance Technologies LLC Trims Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
LPL Financial LLC Sells 21,250 Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
Oramed Invests $36.9 Million In Alpha Tau For Strategic Growth - Finimize
Alpha Tau Medical (DRTS) Secures $36.9M in Direct Offering with Oramed Pharmaceuticals | DRTS Stock News - GuruFocus
Finanzdaten der Oramed Pharmaceuticals Inc-Aktie (ORMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):